2021年急性髓系白血病可测量残留病更新:欧洲白血病网可测量残留病工作组共识文件
欧洲白血病网(ELN)可测量残留病(MRD)工作组基于领域重要进展,通过会议和两阶段德尔菲投票更新2018年ELN MRD推荐,所有推荐按证据等级和共识程度分级。主要变化包括基于二代测序的MRD检测技术规范和不依赖技术的MRD整合评估,并提供MRD阈值、定义MRD反应及结果报告方法。
要点
- 更新2018年ELN MRD推荐,所有推荐按证据等级和共识程度分级。
- 新增基于二代测序的MRD检测技术规范及不依赖技术的MRD整合评估。
- 提供MRD阈值、定义MRD反应,并详述MRD结果报告及多技术联合方法。
核心结论
- 急性髓系白血病(AML)的MRD评估复杂且具有临床相关性,应用、解读、技术操作和报告的标准化方法至关重要。
研究设计与样本
- 欧洲白血病网(ELN)MRD工作组通过面对面和在线会议制定新推荐和修订推荐,并进行两阶段德尔菲投票以优化共识。
- 所有推荐按证据等级和共识程度分级。
主要发现
- 主要变化包括基于二代测序的MRD检测技术规范和不依赖技术的MRD整合评估。
- 其他主题包括MRD作为药物测试的预后和替代终点、MRD评估的技术、材料和适当时机选择,以及MRD评估的临床意义。
- 除流式和分子MRD分析的技术推荐外,还提供MRD阈值、定义MRD反应,并详述MRD结果如何报告及多种技术联合时的合并方法。
关键数值与推荐
- 所有推荐按证据等级和共识程度分级。
- 提供MRD阈值并定义MRD反应。
- 详述MRD结果报告方法及多种技术联合时的合并方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.
引用
- Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021. PMID: 34724563. doi:10.1182/blood.2021013626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。